UB-311 Vaccine Safe, Effective in Mild Alzheimer’s Patients, Phase 2a Trial Suggests

UB-311 Vaccine Safe, Effective in Mild Alzheimer’s Patients, Phase 2a Trial Suggests
United Neuroscience’s Alzheimer's vaccine candidate UB-311 was found safe and well-tolerated, triggering an antibody response against beta-amyloid in most of the patients, according to Phase 2a trial results. "These early results suggest a clinical response and support the continued and rapid development of UB-311. The intent of this Phase 2a study was to acquire directional information on the safety, tolerability and therapeutic potential of UB-311 in patients with Alzheimer's disease,” Mei Mei Hu, CEO of United Neuroscience, said in a press release. UB-311, developed by United Neuroscience, a spin-off of United Biomedical, is a synthetic peptide vaccine designed to trigger an antibody response against beta-amyloid — whose accumulation in the brain is a hallmark of Alzheimer’s disease — clearing it away without causing potentially harmful inflammation. A previous Phase 1 clinical trial (NCT00965588), which tested UB-311 in 19 patients with mild to moderate Alzheimer’s disease, revealed the vaccine was safe and well-tolerated, and able to trigger high lev
Subscribe or to access all post and page content.